Interview with Petr Tor, Country Director, Stallergenes Czech Republic
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Address: Belgicka 20 – 120 00 Praha 2 ,Czech Republic
Tel: +420 222 515 342
Web: http://www.stallergenes.cz/
Stallergenes is a European biopharmaceutical company specialised in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million and more than 500,000 patients were treated with Stallergenes products.
Sublingual immunotherapy tablets
NPPs
Diagnosis products
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can you begin by expounding the results of…
Mr. Kotek, can you please begin by introducing us to the SVOPL and telling us what the mission is here in the Czech Republic? We are a relatively new Association…
See our Cookie Privacy Policy Here
